The group expects to raise nearly $170m.

Can the company add a Car-T string to its stem cell transplant bow?

The first-line Destiny-Gastric05 trial includes a PD-L1-negative cohort.

AstraZeneca and GSK/iTeos's odysseys get a little lonelier still.

After failure of its second-line trial to show an OS benefit, the pressure is on in the front line.

Chengdu Kanghong's KH815 enters human testing this month.

Cabometyx and Pluvicto get the nod, but it’s another knockback for rivoceranib plus camrelizumab.

AACR approaches, along with ASCO abstract titles.

A biliary tract cancer trial hits on response rate, but survival data will be key.

As the non-muscle invasive space is carved up, Aura tries to seize part of it.